Overview

* scPharmaceuticals Q2 revenue of $16 mln beats analyst expectations, per LSEG data

* Net loss of $18 mln missed analyst estimates, per LSEG data

* Company launched FUROSCIX for chronic kidney disease, expanding its market reach

Result Drivers

* REVENUE GROWTH - Net FUROSCIX revenue increased 99% year-over-year to $16 mln, driven by higher demand and expanded market reach

* DOSE INCREASE - Doses shipped to patients rose 117% year-over-year, reflecting strong adoption among prescribers

* CKD MARKET EXPANSION - Launch of FUROSCIX in chronic kidney disease market contributed to revenue growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $16.04 $15.40

Revenue mln mln (5

Analysts

)

Q2 Net Miss -$18.02 -$16.80

Income mln mln (4

Analysts

)

Q2 Beat -$14.29 -$15.90

Income mln mln (4

from Analysts

Operatio )

ns

Q2 Basic -$0.34

EPS

Q2 $30.34

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for scPharmaceuticals Inc is $12.00, about 56.2% above its August 6 closing price of $5.26

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)